Document is current
Any future updates will be listed below
-
Authors
Kim, Mi-Yeon
Kim, Mi Jeong
Lee, Changyeob
Lee, Juwon
Kim, Sang Seong
Hong, Sungho
Kim, Hyoung Tae
Seo, Jinsoo https://orcid.org/0000-0001-6432-6964
Yoon, Ki-Jun https://orcid.org/0000-0003-2985-2541
Han, Sungho
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2019R1C1C1006600)
National Research Foundation of Korea (2020M3A9E4039670)
National Research Foundation of Korea (2018M3C7A1056275)
Korea Health Industry Development Institute (HI18C1801)
Korea Health Industry Development Institute (HI18C1801)
Korea Health Industry Development Institute (HI18C1801)
- License Information
-
More Information
Article History
Received: 15 September 2022
Revised: 9 July 2023
Accepted: 9 July 2023
First Online: 2 October 2023
Competing interests
: M.-Y.K. and S.H. are inventors of PCT/KR2017/013444 and its family patent applications regarding the use of trametinib for neurodegenerative disease. M.-Y.K., M.J.K., and S.H. are stockholders of Genuv Inc. The authors declare no competing interest.
